Meyka Pro banner
DataMEDS AI, Inc.

DataMEDS AI, Inc. Fundamental Analysis (NASDAQ: MEDS)

MEDS●NASDAQ
HealthcareMedical - Distribution
$1.34
$0.61(84.14%)
U.S. Market opens in 51h 34m

DataMEDS AI, Inc. Fundamental Analysis (NASDAQ: MEDS)

DataMEDS AI, Inc. (NASDAQ: MEDS) shows weak financial fundamentals with a PE ratio of -0.06, profit margin of -5.65%, and ROE of 3.56%. The company generates $0.0B in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

Cash Position11.19%
PEG Ratio-0.00

Areas of Concern

ROE3.56%
Operating Margin-3.85%
Current Ratio0.14
We analyze MEDS's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -361.3/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-361.3/100

We analyze MEDS's fundamental strength across five key dimensions:

Efficiency Score

Weak

MEDS struggles to generate sufficient returns from assets.

ROA > 10%
-1.12%

Valuation Score

Excellent

MEDS trades at attractive valuation levels.

PE < 25
-0.06
PEG Ratio < 2
-0.00

Growth Score

Weak

MEDS faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Moderate

MEDS shows balanced financial health with some risks.

Debt/Equity < 1
-11.76
Current Ratio > 1
0.14

Profitability Score

Weak

MEDS struggles to sustain strong margins.

ROE > 15%
3.56%
Net Margin ≥ 15%
-5.65%
Positive Free Cash Flow
No

Key Financial Metrics

Is MEDS Expensive or Cheap?

P/E Ratio

MEDS trades at -0.06 times earnings. This suggests potential undervaluation.

-0.06

PEG Ratio

When adjusting for growth, MEDS's PEG of -0.00 indicates potential undervaluation.

-0.00

Price to Book

The market values DataMEDS AI, Inc. at -2.56 times its book value. This may indicate undervaluation.

-2.56

EV/EBITDA

Enterprise value stands at 0.49 times EBITDA. This is generally considered low.

0.49

How Well Does MEDS Make Money?

Net Profit Margin

For every $100 in sales, DataMEDS AI, Inc. keeps $-5.65 as profit after all expenses.

-5.65%

Operating Margin

Core operations generate -3.85 in profit for every $100 in revenue, before interest and taxes.

-3.85%

ROE

Management delivers $3.56 in profit for every $100 of shareholder equity.

3.56%

ROA

DataMEDS AI, Inc. generates $-1.12 in profit for every $100 in assets, demonstrating efficient asset deployment.

-1.12%

Following the Money - Real Cash Generation

Operating Cash Flow

DataMEDS AI, Inc. generates limited operating cash flow of $-21.73M, signaling weaker underlying cash strength.

$-21.73M

Free Cash Flow

DataMEDS AI, Inc. generates weak or negative free cash flow of $-22.09M, restricting financial flexibility.

$-22.09M

FCF Per Share

Each share generates $-4.90 in free cash annually.

$-4.90

FCF Yield

MEDS converts -2.73% of its market value into free cash.

-2.73%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-0.06

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.00

vs 25 benchmark

P/B Ratio

Price to book value ratio

-2.56

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.79

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

-11.76

vs 25 benchmark

Current Ratio

Current assets to current liabilities

0.14

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

3.56

vs 25 benchmark

ROA

Return on assets percentage

-1.12

vs 25 benchmark

ROCE

Return on capital employed

-36.00

vs 25 benchmark

How MEDS Stacks Against Its Sector Peers

MetricMEDS ValueSector AveragePerformance
P/E Ratio-0.0630.24 Better (Cheaper)
ROE356.14%540.00% Weak
Net Margin-564.77%-2322.00% (disorted) Weak
Debt/Equity-11.760.08 Strong (Low Leverage)
Current Ratio0.145.59 Weak Liquidity
ROA-111.97%-17516.00% (disorted) Weak

MEDS outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews DataMEDS AI, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ